Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

ustekinumab

ustekinumab
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Imudolsa INJECTION, SUBCUTANEOUS 45 mg / 0.5 mL, 90 mg / mL    
Otulfi INJECTION, SUBCUTANEOUS 45 mg / 0.5 mL    
Pyzchiva INJECTION, SUBCUTANEOUS 45 mg / 0.5 mL, 90 mg / mL    
Steqeyma INJECTION, SUBCUTANEOUS 45 mg / 0.5 mL, 90 mg / mL    
Yesintek INJECTION, SUBCUTANEOUS 45 mg / 0.5 mL, 90 mg / mL    
Selarsdi INJECTION, SUBCUTANEOUS 90 mg / mL    
Wezlana INJECTION, SUBCUTANEOUS 90 mg / mL    
Stelara PFS SOLUTION, SUBCUTANEOUS 45 mg / 0.5 mL, 90 mg / mL    
VIEW MORE Monoclonal Antibodies
CLASS
081824
Comments:

Stelara medication guide

Stelara is restricted to Outpatient Medical. Each patient must be evaluated and specifically approved.

Pyzchiva, Imudolsa, Wezlana, Selarsdi, Otulfi, Steqeyma, Yesintek are biosimilars to Stelara; they are classified as therapeutically equivalent and interchangeable to Stelara and other ustekinumab biosimilars for the FDA approved indications and literature support off-label uses. The most cost-effective agent may be used in a given patient, situation, or time period.

Reviewed: October 27, 2010, September 2025  

Ustekinumab (Stelara) Biosimilar Comparison Chart.pdf

Yesintek.pdf       

REMS (Stelara PFS): View FDA REMS Info

Last updated: Oct. 14, 2025






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2025 Rpharmy, LLC ­ All Rights Reserved